Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenzhen trivalent influenza vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Shenzhen trivalent influenza vaccine (Shz-IIV3) is a split-virion trivalent inactivated influenza vaccine developed by Sanofi Pasteur at its facility in Shenzhen, China. It is designed to prevent seasonal influenza by targeting the hemagglutinin (HA) surface proteins of three influenza virus strains (typically two influenza A subtypes and one influenza B lineage), updated annually according to WHO recommendations. Produced according to Chinese pharmacopeia, it is bio-comparative to Sanofi's global Vaxigrip product but manufactured without hydrocortisone. The vaccine stimulates the production of neutralizing antibodies and generates memory B and T cells to provide immunity. It is administered via intramuscular injection and is approved in China for individuals aged 6 months and older.
- Brand names
- Vaxigrip
- Other names
- Shenzhen trivalent inactivated influenza vaccineSanofi Pasteur Shenzhen trivalent influenza vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on Shenzhen trivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen trivalent influenza vaccine.